A Study of JNJ-80948543, a T-cell Redirecting CD79b x CD20 x CD3 Trispecific Antibody, in Participants With Non-Hodgkin Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)
Clinical trial NCT05424822 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT05424822
- Sponsor
- Janssen Research & Development, LLC
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2022-08-18
- Primary completion
- 2025-10-31
- Enrollment
- 167
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.